VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
Filed with HKEX · Stock code 13 · · 5 pages · English
Watch HUTCHMED (China)'s latest callHUTCHMED (China) (HKEX:13) Q2 2026 Earnings Call · Replay · Jul 30Read the transcript of HUTCHMED (China) (HKEX:13) Q2 2026 Earnings CallHUTCHMED (China) Limited on 6ix
Earlier from HUTCHMED (China)
- HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
- HUTCHMED Reports 2026 Interim Results
- HUTCHMED to Announce 2026 Half-Year Financial Results
- HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
- HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Later from HUTCHMED (China)
- HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET Driven EGFR-Mutated Lung Cancer
- Monthly Return of Equity Issuer on Movements in Securities for the month ended September 30, 2026
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
Follow HUTCHMED (China) into a list and get an email when it puts out news.
Follow HUTCHMED (China)